Compare SYSCO Corporation (SYY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs 10X Genomics Inc — how do they compare? SYSCO Corporation trades at $78.33 (market cap $38.47B), while 10X Genomics Inc trades at $81.61 (market cap $10.07B). The key difference: SYSCO Corporation is far larger — about 3.8× 10X Genomics Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and 10X Genomics Inc for 91 Days on average.
| SYY | TXG | |
|---|---|---|
Market Cap | $38.47B | $10.07B |
Volume | 4,808,465 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $97.74 |
52-Week Low | $69.30 | $11.48 |
Typical Hold Time | 77 Days | 91 Days |
Enterprise Value | $51.65B | $9.59B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $78.31, up 1.98% today, with a neutral technical signal and mixed earnings history. The company reported revenue growth to $81.37B in 2025, though net income margin dipped to 2.08%. Recent news highlights a $500M AI efficiency program and a $1.5B senior notes offering, signaling strategic investments. Analyst consensus is bullish with a $85.75 price target, but the stock faces headwinds from high debt levels and competitive pressures.
The outlook for SYY is cautiously optimistic, supported by steady revenue growth and a strong analyst buy rating. Key opportunities include AI-driven cost savings and market expansion, while risks involve elevated leverage and margin compression. Investors should weigh the potential for earnings acceleration against macroeconomic sensitivity in the consumer staples sector.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
